Browsing by Author "Ergen, Arzu"

Now showing 1 - 3 of 3

Adult Rhabdomyosarcoma: Clinical Features and Radiotherapy Outcomes-The Turkish Oncology Group (TOG) Bone and Soft Tissue Sarcoma Study Group
(KARE PUBL, 2018-01-01) Korkmaz Kirakli, Esra; Iribas, Ayca; Ergen, Arzu; Atalar, Banu; Adaoglu, Fulya; Onder Dincbas, Fazilet; Darendeliler, Emin; Anacak, Yavuz; Kamer, Serra
OBJECTIVE Although rhabdomyosarcoma (RMS) is the most frequent soft tissue sarcoma diagnosed in childhood, it represents only 2\%-5\% of adult soft tissue sarcomas. The aim of the present study was to better understand the clinical characteristics, treatment approaches, and outcomes of patients with adult RMS who received radiotherapy (RT) as a component of their multidisciplinary management since there are scarce data on adult RMS due to its rarity. METHODS The medical records of patients with adult RMS who were >= 18 years old and treated with RT between January 1995 and August 2016 in four different radiation centers were evaluated in terms of clinical characteristics, treatment, and follow-up data retrospectively. RESULTS There were 28 patients. The median age at diagnosis was 28 (19-53) years. The most common site of involvement was the head and neck (25\%), and parameningeal region involvement was prominent (92\%) among them. In general, unfavorable site of involvement was markedly higher than favorable ones (82\% vs. 18\%). Alveolar and pleomorphic subtypes compromised 75\% of the cases. Fifteen patients had surgery, 26 chemotherapy, 10 radical intent of RT, 9 adjuvant, 3 preoperative, and 6 palliative. The follow-up time was from 3 to 235 (median 18) months, disease-free survival was between 2 and 48 (median 12) months, and 5-year overall survival (OS) was 25\% (median OS 20 (4-235) months). There were significant differences in terms of survival according to histopathological subtypes (p: 0.017), risk groups (p<0.001), Intergroup Rhabdomyosarcoma Study Group (IRSG) grouping and IRSG staging (p<0.001). CONCLUSION Adult RMS has unfavorable clinical presentation and worse outcome compared with pediatric RMS. Histopathological subtype and risk grouping to define the prognosis used in pediatric cases also might be valid in adult RMS.
LGALS3 and AXIN1 gene variants playing role in the Wnt/beta-catenin signaling pathway are associated with mucinous component and tumor size in colorectal cancer
(ASSOC BASIC MEDICAL SCI FEDERATION BOSNIA \& HERZEGOVINA SARAJEVO, 2016-01-01) Korkmaz, Gurbet; Horozoglu, Cem; Arikan, Soykan; Gural, Zeynep; Saglam, Esra Kaytan; Turan, Saime; Ozkan, Nazli Ezgi; Kahraman, Ozlem Timirci; Yenilmez, Ezgi Nurdan; Duzkoylu, Yigit; Dogan, Mehmet Baki; Zeybek, Umit; Ergen, Arzu; Yaylim, Ilhan
The Wnt pathway alterations have been identified in colorectal and many other cancer types. It has been reported that galectin-3 (which is encoded by the LGALS3 gene) alters the signaling mechanism in the Wnt/beta-catenin pathway by binding to beta-catenin in colon and other cancers. AXIN1 is mainly responsible for the assembly of the beta-catenin destruction complex in the Wnt pathway. This study investigated the relationship of rs4644 and rs4652 variants of the LGALS3 gene and rs214250 variants of the AXIN1 gene to histopathological and clinical properties. Our study included a total of 236 patients, of whom 119 had colorectal cancer (42 women, 77 men) and 117 were healthy controls. Polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) and allele-specific oligonucleotide (ASO) PCR methods were used. In addition, the serum galectin-3 level was studied with the enzyme-linked immunosorbent assay (ELISA) method. For the rs4644 variant of the LGALS(3) gene, the CC genotype a mucinous component was significantly more common than those without a mucinous component (p=0.026). C allele frequency of the rs214250 variant of the AXIN1 gene was significantly correlated to tumor size in the advanced tumor stage (p=0.022). The CCAACT haplotype was more common in colorectal cancer patients (p=0.022). Serum galectin-3 level was higher in the patient group compared to the control group (5.9 +/- 0.69 ng/ml vs. 0.79 +/- 0.01 ng/ml
The modulatory action of C-Vx substance on the immune system in COVID-19
(TAYLOR \& FRANCIS LTD, 2022-01-01) Tahrali, Ilhan; Akdeniz, Nilgun; Yilmaz, Vuslat; Kucuksezer, Umut C.; Oktelik, Fatma B.; Ozdemir, Ozkan; Cetin-Aktas, Esin; Ogutmen, Yelda; Ergen, Arzu; Abaci, Neslihan; Tuzun, Erdem; Oncul, Oral; Deniz, Gunnur
The modulatory effect of C-Vx, a novel therapeutic agent, on the immune system of COVID-19 patients was investigated. The functions of T and NK cells of COVID-19 patients with different disease severity were evaluated by flow cytometry in response to C-Vx stimulation. The levels of pro- and anti-inflammatory cytokines were detected by multiplex assay in supernatants after cell culture with C-Vx. Bradykinin, IRF3, and IFN-alpha levels were also measured by ELISA in the presence or absence of C-Vx stimulation. As a result, increased CD107a expression was observed on NK cells in response to C-Vx addition. The proliferation of T cell subsets was increased by C-Vx, decreasing by disease severity. IL-4 and IL-10 levels were elevated while IFN-gamma and IL-17 levels were reduced in T cells following C-Vx stimulation. However, the levels of pro-inflammatory IL-1 beta, IL-6, IL-8, IFN-gamma and GM-CSF were significantly increased upon C-Vx stimulation. IFN-alpha levels tended to increase after incubation with C-Vx. These findings support an immunomodulatory action of C-Vx on the immune system of patients with a mild and moderate phase of COVID-19.